See more : Netel Holding AB (publ) (NETEL.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Electromed, Inc. (ELMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Electromed, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Daesang Holdings Co., Ltd. (084690.KS) Income Statement Analysis – Financial Results
- SMA Alliance, Inc. (SMAA) Income Statement Analysis – Financial Results
- CT Real Estate Investment Trust (CRT-UN.TO) Income Statement Analysis – Financial Results
- Amcil Limited (AMH.AX) Income Statement Analysis – Financial Results
- Erech Finance Cahalacha Ltd (EFNC.TA) Income Statement Analysis – Financial Results
Electromed, Inc. (ELMD)
About Electromed, Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.72M | 48.07M | 41.66M | 35.76M | 32.47M | 31.30M | 28.70M | 25.86M | 22.99M | 19.41M | 15.49M | 15.10M | 19.52M | 19.00M | 14.30M | 13.00M | 8.75M |
| Cost of Revenue | 12.99M | 11.55M | 10.22M | 8.45M | 7.27M | 7.45M | 5.84M | 5.29M | 5.12M | 5.81M | 4.85M | 4.66M | 5.38M | 5.23M | 3.71M | 3.34M | 2.15M |
| Gross Profit | 41.73M | 36.52M | 31.44M | 27.31M | 25.20M | 23.85M | 22.86M | 20.57M | 17.88M | 13.60M | 10.63M | 10.45M | 14.15M | 13.78M | 10.60M | 9.66M | 6.61M |
| Gross Profit Ratio | 76.26% | 75.98% | 75.47% | 76.36% | 77.61% | 76.19% | 79.64% | 79.53% | 77.75% | 70.07% | 68.66% | 69.18% | 72.45% | 72.50% | 74.08% | 74.30% | 75.47% |
| Research & Development | 656.00K | 916.00K | 1.36M | 1.72M | 1.05M | 583.31K | 251.44K | 596.88K | 380.39K | 315.65K | 466.06K | 603.38K | 920.77K | 1.03M | 600.99K | 357.87K | 271.24K |
| General & Administrative | 33.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.60M | 16.40M | 14.39M | 11.97M | 10.91M | 11.67M | 12.62M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 499.00K | 589.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.49M | 31.60M | 27.11M | 22.44M | 19.94M | 20.45M | 19.60M | 16.40M | 14.39M | 11.97M | 10.91M | 11.67M | 12.62M | 10.87M | 8.20M | 6.85M | 6.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -12.00K | -913.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.87M | 8.20M | 6.85M | 6.00M |
| Operating Expenses | 35.15M | 32.51M | 28.47M | 24.17M | 20.08M | 21.03M | 19.85M | 17.00M | 14.77M | 12.29M | 11.37M | 12.28M | 13.54M | 11.91M | 8.80M | 7.20M | 6.27M |
| Cost & Expenses | 48.14M | 44.06M | 38.69M | 32.62M | 27.35M | 28.48M | 25.69M | 22.29M | 19.88M | 18.10M | 16.23M | 16.93M | 18.92M | 17.13M | 12.51M | 10.54M | 8.42M |
| Interest Income | 455.00K | 78.00K | 25.00K | 39.00K | 120.75K | 90.71K | 0.00 | 17.04K | 0.00 | 284.00 | 12.39K | 16.72K | 8.40K | 10.92K | 6.42K | 8.75K | 24.82K |
| Interest Expense | 0.00 | 0.00 | 25.00K | 0.00 | 0.00 | 0.00 | 19.87M | 66.91K | 66.81K | 85.99K | 91.40K | 133.56K | 177.13K | 191.33K | 269.85K | 279.19K | 501.69K |
| Depreciation & Amortization | 841.00K | 613.00K | 628.00K | 610.00K | 738.23K | 925.23K | 790.03K | 755.13K | 738.70K | 736.22K | 695.55K | 589.86K | 532.63K | 449.47K | 351.75K | 318.95K | 268.40K |
| EBITDA | 7.42M | 4.62M | 3.60M | 3.75M | 5.86M | 3.74M | 3.80M | 4.32M | 3.85M | 2.05M | -32.65K | -1.24M | 1.15M | 2.33M | 2.15M | 2.77M | 627.43K |
| EBITDA Ratio | 13.56% | 9.61% | 8.64% | 10.49% | 18.04% | 11.96% | 13.24% | 16.72% | 16.74% | 10.54% | -0.21% | -8.08% | 5.88% | 12.21% | 15.06% | 21.41% | 7.17% |
| Operating Income | 6.58M | 4.01M | 2.97M | 3.14M | 5.12M | 2.82M | 3.01M | 3.57M | 3.11M | 1.31M | -740.59K | -1.83M | 606.34K | 1.87M | 1.80M | 2.46M | 334.22K |
| Operating Income Ratio | 12.03% | 8.34% | 7.13% | 8.78% | 15.76% | 9.00% | 10.48% | 13.80% | 13.52% | 6.75% | -4.78% | -12.10% | 3.11% | 9.84% | 12.56% | 18.89% | 3.82% |
| Total Other Income/Expenses | 455.00K | 78.00K | 25.00K | 27.00K | 120.75K | 101.82K | -276.35K | -49.87K | -66.81K | -85.71K | -79.00K | -116.88K | -168.73K | -191.33K | -263.43K | -270.45K | -476.87K |
| Income Before Tax | 7.04M | 4.09M | 3.00M | 3.17M | 5.24M | 2.91M | 3.03M | 3.52M | 3.04M | 1.22M | -819.59K | -1.94M | 437.61K | 1.68M | 1.53M | 2.19M | -142.65K |
| Income Before Tax Ratio | 12.86% | 8.50% | 7.19% | 8.86% | 16.14% | 9.29% | 10.55% | 13.61% | 13.23% | 6.31% | -5.29% | -12.87% | 2.24% | 8.83% | 10.71% | 16.81% | -1.63% |
| Income Tax Expense | 1.89M | 920.00K | 692.00K | 805.00K | 1.08M | 940.00K | 1.13M | 1.29M | 830.00K | 132.00K | 469.00K | -615.00K | 251.00K | 623.00K | 599.00K | 830.00K | -427.00K |
| Net Income | 5.15M | 3.17M | 2.31M | 2.36M | 4.16M | 1.97M | 1.90M | 2.23M | 2.21M | 1.09M | -1.29M | -1.33M | 186.61K | 1.06M | 916.34K | 1.33M | 267.85K |
| Net Income Ratio | 9.41% | 6.59% | 5.53% | 6.61% | 12.81% | 6.29% | 6.63% | 8.62% | 9.62% | 5.63% | -8.32% | -8.80% | 0.96% | 5.55% | 6.41% | 10.25% | 3.06% |
| EPS | 0.60 | 0.37 | 0.27 | 0.28 | 0.50 | 0.24 | 0.23 | 0.27 | 0.27 | 0.13 | -0.16 | -0.16 | 0.02 | 0.14 | 0.15 | 0.22 | 0.05 |
| EPS Diluted | 0.58 | 0.36 | 0.26 | 0.27 | 0.47 | 0.23 | 0.22 | 0.26 | 0.27 | 0.13 | -0.16 | -0.16 | 0.02 | 0.13 | 0.15 | 0.22 | 0.04 |
| Weighted Avg Shares Out | 8.56M | 8.46M | 8.47M | 8.57M | 8.40M | 8.31M | 8.21M | 8.17M | 8.14M | 8.12M | 8.05M | 8.11M | 8.11M | 7.82M | 6.08M | 5.99M | 5.44M |
| Weighted Avg Shares Out (Dil) | 8.86M | 8.70M | 8.77M | 8.91M | 8.83M | 8.63M | 8.62M | 8.46M | 8.25M | 8.15M | 8.11M | 8.11M | 8.11M | 7.84M | 6.11M | 6.02M | 6.45M |
Electromed, Inc. (ELMD) CEO Kathleen Skarvan on Q2 2022 Results - Earnings Call Transcript
Electromed, Inc. (ELMD) CEO Kathleen Skarvan on Q2 2022 Results - Earnings Call Transcript
Electromed, Inc. Announces Second Quarter Financial Results
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for its fiscal 2022 second quarter ended December 31, 2021. Management will host a conference call at...
Electromed, Inc. (ELMD) Upgraded to Buy: Here's What You Should Know
Electromed, Inc. (ELMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Electromed, Inc. to Participate in the Sidoti December Virtual Micro Cap Investor Conference
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Kathleen Skarvan, President and Chief Executive Officer, and Mike MacCourt, Chief Financial Officer, are scheduled to participate in...
Bears are Losing Control Over Electromed, Inc. (ELMD), Here's Why It's a 'Buy' Now
Electromed, Inc. (ELMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher...
Electromed, Inc. (ELMD) Lags Q1 Earnings Estimates
Electromed, Inc. (ELMD) delivered earnings and revenue surprises of -16.67% and 11.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Electromed, Inc. (ELMD) CEO Kathleen Skarvan on Q1 2022 Results - Earnings Call Transcript
Electromed, Inc. (ELMD) CEO Kathleen Skarvan on Q1 2022 Results - Earnings Call Transcript
Electromed, Inc. Schedules its First Quarter Fiscal 2022 Financial Results Conference Call for November 9, 2021 at 5:00 p.m. ET
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2022 first quarter ended September 30, 2021,...
Electromed, Inc. Schedules its First Quarter Fiscal 2022 Financial Results Conference Call for November 9, 2021 at 5:00 p.m. ET
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2022 first quarter ended September 30, 2021,...
Electromed, Inc. (ELMD) CEO Kathleen Skarvan on Q4 2021 Results - Earnings Call Transcript
Electromed, Inc. (ELMD) CEO Kathleen Skarvan on Q4 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports